Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set

Palvella Therapeutics (NASDAQ:PVLA) announced FDA Priority Review for QTORIN 3.9% gel to treat microcystic lymphatic malformations, with a target action date of February 28, 2027. The application is based on positive Phase 3 SELVA study results, showing significant efficacy and a good safety profile. The therapy has received Breakthrough Therapy, Fast Track, and Orphan Drug designations. Palvella plans a potential U.S. launch in early 2027, pending approval.

Palvella Therapeutics (PVLA) received FDA acceptance and Priority Review for its QTORIN rapamycin NDA, targeting a February 28, 2027 decision. The NDA seeks approval to treat microcystic lymphatic malformations, a condition with no current FDA-approved therapies. Phase 3 SELVA results showed statistical significance across all efficacy endpoints. Palvella plans a potential U.S. launch in early 2027 if approved.

Palvella Therapeutics (PVLA) presented its rare-disease strategy at Chardan's conference, targeting a commercial launch in 2025. The company raised $230M in 2024, filed an NDA for QTORIN rapamycin, and expects an FDA decision by late October. Palvella is expanding its pipeline to six indications by year-end, with a focus on skin and vascular anomaly diseases. Management anticipates peak sales of $1B-$3B for its lead programs.

H.C. Wainwright reiterated a Buy rating and $246 price target for Palvella Therapeutics (PVLA) after positive pediatric data from dermatology conferences. The stock trades at $122.96, with a Strong Buy consensus and targets ranging from $205 to $267. Palvella presented data from Phase 3 SELVA and Phase 2 TOIVA trials, showing strong responses in young patients. The company reported a Q2 loss of $1.52 per share, wider than expected, but has $251 million in cash.

Raymond James reiterated a Strong Buy rating and $226.00 price target for Palvella Therapeutics (NASDAQ:PVLA) after its presentation at a dermatology conference. The data showed positive results for QTORIN rapamycin in pediatric patients, supporting a broad potential label. Despite an 8.2% weekly decline, the stock is up 74% over the past year. Palvella reported a wider-than-expected Q2 loss but has $251 million in cash for development.

William Blair initiated coverage on Palvella Therapeutics (PVLA) with an Outperform rating and a $266 price target, citing its QTORIN platform. The stock, trading at $127.34, has risen 74% over the past year. Palvella reported a Q2 loss of $1.52 per share, wider than expected, but shares rose due to investor interest in its cash reserves and trial progress. The company expects FDA approval for its lead drug, QTORIN rapamycin, in early 2027, with projected U.S. sales of $800 million by 2032.